Myelodysplastic/myeloproliferative neoplasms

The EU has approved 1 indication of 1 drug in myelodysplastic/myeloproliferative neoplasms. It needs a biomarker result: PDGFR (1).

Line of therapy

Approved indications, Myelodysplastic/myeloproliferative neoplasms
DrugBiomarker requirementRegimenSettingConditions
PDGFR fusion1
Imatinib
Glivec
Monotherapy
Any line
None

Biomarkers in myelodysplastic/myeloproliferative neoplasms

Label wording1

The sentence from section 4.1 of the SmPC that each indication above comes from.

  1. Imatinib (Glivec)
    adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.